Research and Development Project Started
929 Mainland Street
Vancouver, BC V6B 1S3
Phone
Fax
(604) 928-8913
(604) 628-0129
Email [email protected]
Website www.lexston.ca
NEWS RELEASE
LEXSTON INITIATES RESEARCH AND DEVELOPMENT PROJECT
USING PSYCHEDELIC COMPOUND 5-Me0-DMT
Vancouver, British Columbia, September 23, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (the
“Company” or “Lexston”) is pleased to announce that the company’s scientific research and development
division led by Chief Science Officer, Dr. Philippe Henry, has begun work on its tryptamine pipeline with
an initial focus on 5 -Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) at its newly acquired Zen alytic
Laboratories.
With confirmation from Health Canada’s Controlled Substances Directorate to proceed with
characterization work on the target molecule, 5 -MeO-DMT, Lexston’s scientists have moved ahead with
its plans to develop methods for the identification and quantification of this target tryptamine. The
Company has also successfully developed a High Pressure Liquid Chromatography (HPLC) assay for the
determination and purity of 5-MeO-DMT, thus paving the way for future product development activities.
Additionally, it has successfully collected Near- Infrared spectra (NIRs) from the purified substance to
develop a portable rapid technique for the identification and quantification of tryptamine formulations at
the point-of-care.
The Company is explorin g different naturally derived botanical sources of 5 -MeO-DMT, the use of
different solvents and delivery systems for a formulation of a sub -psychoactive dosage . Based on its
neuro-vasocontraction abilities this formulation will be used in conj unction with clinical partners
specifically targeted for the alternative treatment of migraines and cluster headaches.
In support of clinical applications, the Lexston team is also collecting serotonin and other receptor affinity
data for 5 -MeO-DMT, its metabolites and other closely related tryptamines. 5-MeO-DMT possesses
unique pharmacodynamic and pharmacokinetic properties imparted by its specificity for serotonin
receptors 5HT-1a,7,6,1d and dopamine D1. Unravelling the mechanism underlying the mode of action of
this tryptamine is expected to shed light on potential novel treatments for major depressive disorders and
addiction.
“We believe that the 5 -MeO pathway is fundamental to the development of multiple novel treatments
and the activation of a tryptamine production pipeline early in the upcoming psychedelic trend is vital to
accelerating the access to treatment with these potentially life altering compounds.” stated Graeme Staley,
Director of Lexston.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research
services. Lexston is also in the process of securing licensing under the exemptions prescribed by section
Page | 2
56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the
psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in
the lab and point of care. Lexston intends to develop and validate me thods for standardized
manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health
and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
Forward Looking Information
All statements in this press release, other than statements of historical fact, are “forward- looking
information” with respect to the Company and its business within the meaning of applicable securiti es
laws, including the business plans and prospects of the Company. The Company provides forward-looking
statements for the purpose of conveying information about current expectations and plans relating to the
future and readers are cautioned that such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and uncertainties that may be general or specific and
which give rise to the possibility that expectations, forecasts, predictions, projections, or conclusions will
not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and
priorities will not be achieved. These risks and uncertainties include but are not limited to those identified
and reported in the Company’s public filings under its SEDAR profile at www.sedar.com. Although the
Company has attempted to identify important factors that could cause actual actions, events, or results
to differ materially from those described in forward-looking information, there may be other factors that
cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance
that such information will prove to be accurate as actual results and future events could differ materially
from those anticipated in such statements. The Company disclaims any intention or obligation to update
or revise any forward- looking information, whether as a result of new information, future events or
otherwise unless required by law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the
adequacy or accuracy of this release.